RU2337685C2 - Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза - Google Patents

Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза Download PDF

Info

Publication number
RU2337685C2
RU2337685C2 RU2006126828/15A RU2006126828A RU2337685C2 RU 2337685 C2 RU2337685 C2 RU 2337685C2 RU 2006126828/15 A RU2006126828/15 A RU 2006126828/15A RU 2006126828 A RU2006126828 A RU 2006126828A RU 2337685 C2 RU2337685 C2 RU 2337685C2
Authority
RU
Russia
Prior art keywords
anesthesia
compound
formula
pharmaceutically acceptable
butyl
Prior art date
Application number
RU2006126828/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2006126828A (ru
Inventor
Мэри Энн ХИКМАН (US)
Мэри Энн ХИКМАН
Кристин Эдна МИСКЕЛЛ (US)
Кристин Эдна МИСКЕЛЛ
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of RU2006126828A publication Critical patent/RU2006126828A/ru
Application granted granted Critical
Publication of RU2337685C2 publication Critical patent/RU2337685C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RU2006126828/15A 2004-01-30 2005-01-06 Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза RU2337685C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54069704P 2004-01-30 2004-01-30
US60/540,697 2004-01-30

Publications (2)

Publication Number Publication Date
RU2006126828A RU2006126828A (ru) 2008-03-10
RU2337685C2 true RU2337685C2 (ru) 2008-11-10

Family

ID=34910695

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006126828/15A RU2337685C2 (ru) 2004-01-30 2005-01-06 Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза

Country Status (14)

Country Link
US (1) US20070155782A1 (cg-RX-API-DMAC7.html)
EP (1) EP1713479A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007519701A (cg-RX-API-DMAC7.html)
KR (1) KR100880391B1 (cg-RX-API-DMAC7.html)
CN (1) CN1913893A (cg-RX-API-DMAC7.html)
AU (1) AU2005216706B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507325A (cg-RX-API-DMAC7.html)
CA (1) CA2554823A1 (cg-RX-API-DMAC7.html)
IL (1) IL176830A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06007964A (cg-RX-API-DMAC7.html)
NO (1) NO20062965L (cg-RX-API-DMAC7.html)
RU (1) RU2337685C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005082366A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200605149B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2489765C1 (ru) * 2012-01-10 2013-08-10 Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") Способ изготовления газонаполненного разрядника

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034099T2 (en) 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN114984223B (zh) * 2022-05-31 2023-06-20 中国人民解放军陆军军医大学第二附属医院 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用
AT527172A1 (de) * 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung
WO2026099213A1 (fr) * 2024-11-05 2026-05-15 Ceva Sante Animale Compositions comprenant du maropitant base et leurs utilisations
FR3168163A1 (fr) * 2024-11-05 2026-05-08 Ceva Sante Animale Compositions aqueuses comprenant du maropitant et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US540897A (en) 1895-06-11 Harold f
US540644A (en) 1895-06-11 del yalle
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WO 03009848 A1 (PFIZER PRODUCTS INC. et al.), 06.02.2003. WO 0073304 A1 (PFIZER PRODUCTS INC. et al.), 07.12.2000. Gardner C, Perren M. Inhibition of anaesthetic-induced emesis by a NKl or 5-HT3. receptor antagonist in the house musk shrew, Suncus murinus. Neuropharmacology. 1998Dec;37(12):1643-4. Diemunsch P, et al. Antiemetic activity of the NKl receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth. 1999 Feb;82(2):274-6. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2489765C1 (ru) * 2012-01-10 2013-08-10 Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") Способ изготовления газонаполненного разрядника

Also Published As

Publication number Publication date
WO2005082366A1 (en) 2005-09-09
BRPI0507325A (pt) 2007-07-03
AU2005216706A1 (en) 2005-09-09
EP1713479A1 (en) 2006-10-25
MXPA06007964A (es) 2007-01-26
WO2005082366A8 (en) 2005-12-15
IL176830A0 (en) 2006-10-31
KR100880391B1 (ko) 2009-01-30
US20070155782A1 (en) 2007-07-05
NO20062965L (no) 2006-07-21
ZA200605149B (en) 2007-11-28
RU2006126828A (ru) 2008-03-10
JP2007519701A (ja) 2007-07-19
AU2005216706B2 (en) 2007-11-29
CA2554823A1 (en) 2005-09-09
KR20060127934A (ko) 2006-12-13
CN1913893A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
KR101747476B1 (ko) 마취 제제
CN103998046B (zh) 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
JP5415942B2 (ja) 処置の方法およびその処置に有用な薬剤
JP5565794B2 (ja) ピモベンダン及びシクロデキストリンの錯体を含む液体製剤
CN102159077A (zh) 用于治疗神经性疼痛的方法
US20240374568A1 (en) Parenteral liquid preparation comprising carbamate compound
CN112370450A (zh) 格拉匹纶组合物及其使用方法
Martín Bellido et al. Clinical review of the pharmacological and anaesthetic effects of alfaxalone in dogs
AU2005216706B2 (en) NK-1 receptor antagonists anesthesia recovery
US20220071996A1 (en) Oral formulations of branaplam
JP5462797B2 (ja) 注射可能なメクリジン製剤および方法
JP2007519702A (ja) ニューロキニン受容体拮抗薬及びシクロデキストリンからなる医薬組成物、ならびに注射部位の耐容性を改善するための方法
JP2010502691A (ja) 抗腫瘍剤を含む水性製剤
HK1100640A (en) Nk-1 receptor antagonists anesthesia recovery
AU2024262341A1 (en) Maropitant formulation
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20100107